Endeavor Private Wealth Inc. Makes New $45,000 Investment in Bristol-Myers Squibb (NYSE:BMY)

Endeavor Private Wealth Inc. bought a new stake in shares of Bristol-Myers Squibb (NYSE:BMY) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 804 shares of the biopharmaceutical company’s stock, valued at approximately $45,000.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Mutual Advisors LLC boosted its position in Bristol-Myers Squibb by 1.4% during the 4th quarter. Mutual Advisors LLC now owns 55,393 shares of the biopharmaceutical company’s stock valued at $3,123,000 after acquiring an additional 741 shares in the last quarter. Wendell David Associates Inc. lifted its stake in shares of Bristol-Myers Squibb by 5.2% in the 4th quarter. Wendell David Associates Inc. now owns 20,201 shares of the biopharmaceutical company’s stock valued at $1,143,000 after purchasing an additional 992 shares during the period. Traynor Capital Management Inc. boosted its position in shares of Bristol-Myers Squibb by 4.3% during the fourth quarter. Traynor Capital Management Inc. now owns 7,275 shares of the biopharmaceutical company’s stock valued at $411,000 after purchasing an additional 300 shares in the last quarter. Janney Montgomery Scott LLC grew its stake in Bristol-Myers Squibb by 29.5% in the fourth quarter. Janney Montgomery Scott LLC now owns 954,727 shares of the biopharmaceutical company’s stock worth $53,999,000 after purchasing an additional 217,603 shares during the period. Finally, Magnus Financial Group LLC raised its holdings in Bristol-Myers Squibb by 28.4% in the fourth quarter. Magnus Financial Group LLC now owns 7,814 shares of the biopharmaceutical company’s stock worth $442,000 after purchasing an additional 1,727 shares in the last quarter. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the stock. Leerink Partners raised shares of Bristol-Myers Squibb from a “market perform” rating to an “outperform” rating and upped their target price for the stock from $55.00 to $73.00 in a research report on Tuesday, November 12th. Cantor Fitzgerald restated a “neutral” rating and issued a $50.00 price objective on shares of Bristol-Myers Squibb in a report on Friday, October 18th. Bank of America reiterated a “neutral” rating and set a $63.00 target price on shares of Bristol-Myers Squibb in a report on Tuesday, December 10th. Jefferies Financial Group upgraded Bristol-Myers Squibb from a “hold” rating to a “buy” rating and upped their price target for the stock from $63.00 to $70.00 in a research note on Monday, December 16th. Finally, Daiwa America upgraded Bristol-Myers Squibb from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, November 13th. Two equities research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, four have assigned a buy rating and three have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Bristol-Myers Squibb currently has an average rating of “Hold” and an average target price of $56.27.

Bristol-Myers Squibb Stock Performance

BMY stock opened at $57.11 on Thursday. The company has a market cap of $115.83 billion, a P/E ratio of -15.91, a price-to-earnings-growth ratio of 2.02 and a beta of 0.45. The company has a debt-to-equity ratio of 2.83, a current ratio of 1.24 and a quick ratio of 1.09. Bristol-Myers Squibb has a 1 year low of $39.35 and a 1 year high of $61.08. The stock’s fifty day moving average price is $57.39 and its 200-day moving average price is $52.36.

Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, October 31st. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.49 by $0.31. Bristol-Myers Squibb had a positive return on equity of 11.94% and a negative net margin of 15.30%. The business had revenue of $11.89 billion for the quarter, compared to analysts’ expectations of $11.26 billion. During the same period last year, the firm posted $2.00 earnings per share. The business’s revenue for the quarter was up 8.4% on a year-over-year basis. On average, equities analysts forecast that Bristol-Myers Squibb will post 0.92 earnings per share for the current year.

Bristol-Myers Squibb Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, February 3rd. Shareholders of record on Friday, January 3rd will be given a $0.62 dividend. The ex-dividend date of this dividend is Friday, January 3rd. This is an increase from Bristol-Myers Squibb’s previous quarterly dividend of $0.60. This represents a $2.48 annualized dividend and a yield of 4.34%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently -69.08%.

Insider Transactions at Bristol-Myers Squibb

In other Bristol-Myers Squibb news, SVP Phil M. Holzer sold 700 shares of Bristol-Myers Squibb stock in a transaction that occurred on Monday, November 4th. The shares were sold at an average price of $55.62, for a total transaction of $38,934.00. Following the transaction, the senior vice president now owns 11,760 shares of the company’s stock, valued at $654,091.20. The trade was a 5.62 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Samit Hirawat acquired 1,830 shares of Bristol-Myers Squibb stock in a transaction dated Friday, November 1st. The stock was purchased at an average cost of $54.67 per share, with a total value of $100,046.10. Following the completion of the purchase, the executive vice president now owns 62,109 shares of the company’s stock, valued at approximately $3,395,499.03. This represents a 3.04 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 0.09% of the company’s stock.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.